Mounjaro week one: what side effects and appetite suppression really look like

What did @lozs.mj.journey actually say?

Honestly? Not much that's medically verifiable. The transcript captured in this video appears to be song lyrics, not a narrated health update. The caption, however, tells a clearer story: one week on Mounjaro (tirzepatide), side effects present, no meaningful appetite suppression yet, and a self-directed plan to count calories and move more. That caption is where the real claims live.

The creator is transparent about their experience, which is more than a lot of GLP-1 content creators manage. They're not overselling results or claiming dramatic early weight loss. They're saying it hasn't clicked yet, and they're putting the responsibility back on themselves. That kind of framing is rare and worth acknowledging.

Does the science back up the week-one experience?

Yes, largely. A slow start with tirzepatide is completely normal, and the side-effect profile the creator references is well-documented. The absence of appetite suppression in week one is not a failure of the drug or the person.

Tirzepatide works as a dual GIP and GLP-1 receptor agonist. Clinical protocols typically start patients at 2.5 mg weekly for the first four weeks before escalation. At that starting dose, appetite suppression can be modest or undetectable. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed the most significant weight loss effects emerged over months, not days. Nausea, fatigue, and gastrointestinal discomfort are the most commonly reported early side effects, appearing in roughly 20 to 40 percent of patients in early titration phases. The creator's experience sits squarely within what the data predicts.

What did they get wrong, or right?

The implicit suggestion that not feeling appetite suppression in week one means they need to "work harder" is worth pushing back on. That framing, while well-intentioned, misunderstands how tirzepatide works at the dose-titration stage.

Blaming yourself for needing to count calories more carefully when the drug hasn't reached its therapeutic threshold yet is not a clinical strategy, it's self-pressure that the evidence doesn't support. Davies et al. (2021, The Lancet) noted that behavioral interventions alongside GLP-1 therapy do improve outcomes, but the mechanism here is pharmacological escalation, not willpower. The creator is right that lifestyle effort matters. They're wrong to frame week one suppression absence as something they caused or need to fix through harder effort. That said, their willingness to stay patient and "trust the process" is genuinely aligned with how these drugs are designed to work.

What should you actually know?

If you're on tirzepatide and nothing feels different in week one, that is not unusual. The drug is titrated slowly precisely to reduce side effects, which means the appetite-suppressing effects also build gradually. Most patients don't hit the 5 mg or 10 mg doses where significant suppression is reliably reported until weeks four to twelve.

• The SURMOUNT-1 trial found average weight loss of 20.9 percent body weight at the highest dose over 72 weeks. Week one is not the window you judge this drug by.
• Side effects like nausea are real and typically peak during dose increases, then settle. Eating smaller meals and avoiding high-fat foods can help manage early GI symptoms.
• Calorie awareness alongside GLP-1 therapy does support better outcomes, but it works best once appetite signals from the medication are active, not as a substitute for them.
• Anyone experiencing severe vomiting, inability to keep fluids down, or sharp abdominal pain should contact their prescriber. These are not normal side effects to push through.

The bottom line

This creator is doing something genuinely useful: showing the unglamorous, slow, side-effect-laden start that most GLP-1 content skips over. The experience they describe in the caption is consistent with what clinical data shows for tirzepatide's early titration phase. The only misstep is framing the absence of week-one suppression as a personal effort problem rather than a pharmacological timing issue. That's a common misconception worth correcting, not a reason to dismiss their experience.